WebDoctor Encyclopedia

Central nervous system Childhood

Subependymal giant cell astrocytoma (SEGA)

Subependymal giant cell astrocytoma (SEGA) is a benign, slow-growing brain tumour seen in people with tuberous sclerosis complex. It can block brain fluid flow and cause hydrocephalus, and is treated with surgery or the mTOR inhibitor everolimus.

Medically reviewed Last reviewed October 19, 2026

What is subependymal giant cell astrocytoma?

Subependymal giant cell astrocytoma (SEGA) is a slow-growing, non-cancerous (benign) brain tumour that occurs almost only in people with tuberous sclerosis complex (TSC). TSC is a genetic condition that causes benign growths in many organs, including the brain, skin, kidneys, heart and lungs.

SEGAs grow on the wall of the fluid-filled spaces of the brain (the ventricles), usually near a narrow passage called the foramen of Monro. Here, cerebrospinal fluid flows from one ventricle to the next. A growing SEGA can block this passage, causing fluid to build up in the brain (hydrocephalus), which can be dangerous.

SEGAs develop in about one in ten to one in five people with TSC, mostly during childhood and the teenage years. They rarely start after the age of 25. The World Health Organization classes SEGA as a CNS WHO grade 1 tumour, the lowest grade.

There are two main treatments: surgery to remove the tumour and everolimus, a tablet that targets the faulty growth signal behind TSC (Franz et al., 2013).

1. Key facts at a glance

Feature Details
Type of tumour Benign, slow-growing brain tumour (CNS WHO grade 1)
Linked condition Tuberous sclerosis complex in nearly all cases
How common About 5-20% of people with TSC
Typical age Childhood and adolescence, usually before 20-25
Location Wall of the lateral ventricles near the foramen of Monro
Main danger Blockage of fluid flow, causing hydrocephalus
Genes involved TSC1 or TSC2
Main treatments Surgery or everolimus (an mTOR inhibitor)
Outlook Very good with monitoring and timely treatment

2. Tuberous sclerosis complex in brief

Feature Details
Cause A change in the TSC1 or TSC2 gene
Inheritance Can be inherited (autosomal dominant) or arise for the first time in a child
Brain features Tubers, subependymal nodules and SEGAs
Other features Epilepsy, learning difficulties, autism, skin patches, kidney angiomyolipomas, heart rhabdomyomas, lung changes
Mechanism Loss of TSC function switches on the mTOR growth pathway

Subependymal nodules are small, harmless bumps on the ventricle walls found in most people with TSC. A SEGA is thought to grow from one of these nodules. A nodule near the foramen of Monro that is over 1 cm or keeps growing is usually regarded as a SEGA.

3. Causes and risk factors

Risk factor Notes
Tuberous sclerosis complex The main and almost only risk factor
TSC2 gene change Often linked with more severe TSC features
Younger age Most SEGAs appear and grow in childhood
Growing subependymal nodules Nodules near the foramen of Monro need closer monitoring

In TSC, both copies of the TSC1 or TSC2 gene are lost in the tumour cells. This removes a brake on the mTOR pathway, which controls cell growth, so cells grow larger and divide more. This is why mTOR inhibitors such as everolimus can shrink SEGAs.

4. How does it look

On MRI

Feature Description
Location Near the foramen of Monro, in the lateral ventricle
Size Usually over 1 cm; may grow slowly over months or years
Enhancement Bright after contrast injection
Calcification Often contains calcium, best seen on CT
Hydrocephalus Enlarged ventricles if fluid flow is blocked

Under the microscope

Feature Description
Cells Large cells, some looking like nerve cells and others like astrocytes
Pattern Sheets and clusters, often arranged around blood vessels
Cell division Rare
Markers Mixed glial and neuronal markers, reflecting its glioneuronal nature

Despite the name “astrocytoma”, SEGA behaves very differently from aggressive gliomas. It does not spread through the brain or to other parts of the body.

5. Symptoms

Many SEGAs are found on routine MRI scans before they cause symptoms. Symptoms usually come from raised pressure inside the head when fluid flow is blocked.

Symptoms of raised pressure (hydrocephalus)

  • Headaches, often worse in the morning or on lying down
  • Nausea and vomiting
  • Drowsiness or reduced alertness
  • Blurred or double vision
  • Irritability or changes in behaviour
  • In babies, an enlarging head or a bulging soft spot

Other symptoms

Symptom Notes
Worsening seizures May reflect raised pressure or the tumour itself
Changes in learning or behaviour Can be subtle and gradual
Weakness Uncommon

When to seek urgent help

Seek emergency care if a person with TSC develops a severe headache, repeated vomiting, unusual sleepiness, sudden vision problems or a change in seizure pattern. Sudden blockage of fluid flow can be life-threatening.

People with TSC may have communication difficulties, so carers should watch for changes in behaviour, sleep or feeding that might signal a problem.

Emergency plan

Families of people with TSC and SEGA are often given a written emergency plan. It usually includes:

  • The warning signs of raised pressure
  • The name and number of the neurosurgical or TSC team
  • A summary of the person’s diagnosis, medicines and recent scans
  • Instructions to tell emergency staff that the person has a SEGA and may need an urgent brain scan

6. Diagnosis

Test Purpose
Brain MRI with contrast The main test for detecting and monitoring SEGA
CT scan Shows calcification; used in emergencies
Eye examination Checks for swelling at the back of the eye (papilloedema)
Genetic testing Confirms TSC1 or TSC2 change
Neurological examination Assesses symptoms and signs

Surveillance in tuberous sclerosis complex

International TSC guidelines recommend regular brain MRI for people with TSC without symptoms, typically every 1-3 years until about age 25. Scans are done more often if a nodule is growing or if the ventricles are enlarging.

7. Treatment

Treatment depends on the size and growth of the tumour, whether there is hydrocephalus, and the person’s wider TSC features. Decisions are made by a TSC clinic or neuro-oncology team.

Options

Option When used
Monitoring Small, stable SEGAs without symptoms
Surgery Acute hydrocephalus, rapidly growing tumours, or when complete removal is achievable
Everolimus Growing SEGAs, tumours in hard-to-reach places, or people who prefer to avoid surgery
Shunt or endoscopic procedure To drain fluid when hydrocephalus is present
Laser ablation or radiosurgery Occasionally, in specialist centres

Surgery

Surgery aims to remove the whole tumour and restore normal fluid flow. It is the preferred option for sudden, severe hydrocephalus.

Outcome (pooled surgical series) Result
Complete removal About 81% of operations
Recurrence About 12%, usually after partial removal
Permanent complications About 6%
Death About 5%

These figures come from a review of 18 surgical series including 263 patients (Danassegarane et al., 2022). Results in modern specialist centres can be better.

Surgery or everolimus?

Factor Surgery Everolimus
Speed of effect Immediate relief of blockage Gradual shrinkage over months
Best for Sudden hydrocephalus; a single, accessible tumour Growing tumours, several TSC problems, high surgical risk
Duration One operation, sometimes repeated Usually long-term daily tablets
Main risks Bleeding, infection, brain injury, need for a shunt Mouth ulcers, infections, metabolic changes
Other TSC benefits None May also help seizures, kidney and skin lesions

What brain surgery involves

Stage What happens
Before MRI planning, blood tests and an anaesthetic review
Operation Through an opening in the skull, often via the corpus callosum or a small opening in the brain surface; endoscopic surgery for some tumours
After A day or more in intensive care, then the ward
Hospital stay Usually around a week
Recovery Gradual return to school or work over several weeks

Everolimus

Everolimus is a tablet taken once a day. The dose is adjusted using blood level tests.

Trial result Finding
EXIST-1 (117 patients) 35% had at least a halving of SEGA volume with everolimus, compared with none on placebo
Extension (111 patients) About half achieved at least a halving of SEGA volume over a median of more than 2 years

Results from Franz et al. (2013) and Franz et al. (2014). Everolimus can also reduce seizures and shrink kidney angiomyolipomas in TSC. SEGAs often regrow if the drug is stopped, so treatment is usually long-term.

Side effects of everolimus

Side effect Notes
Mouth ulcers and sore mouth (stomatitis) The most common; special mouthwashes help
Infections Colds, chest infections; report fever promptly
Raised cholesterol and blood sugar Checked with blood tests
Rash or acne-like spots Usually mild
Irregular periods In some girls and women
Delayed wound healing Treatment may be paused around surgery

8. Outlook (prognosis)

Situation Outlook
Small SEGA under monitoring Excellent; many never need treatment
SEGA treated with surgery Usually very good when completely removed
SEGA treated with everolimus Tumour control in most people while on treatment
Untreated growing SEGA Risk of hydrocephalus and serious harm

SEGA does not turn into cancer. For most people with TSC, long-term health depends more on epilepsy, learning and behaviour and kidney and lung involvement than on the SEGA itself.

SEGA in adults

Most SEGAs are found in children, but adults with TSC may still have one that was found earlier, or occasionally a newly growing lesion. Adult SEGAs tend to grow very slowly, and many simply need monitoring. Adults moving from children’s services should make sure their brain scans continue at the interval recommended by their TSC team.

9. Follow-up

Follow-up Purpose
Brain MRI Every few months after starting treatment, then yearly or less often
Everolimus blood levels Adjust the dose
Blood tests Cholesterol, sugar, blood count, liver and kidney function
Eye checks If hydrocephalus is suspected
TSC clinic review Coordinates care for all TSC features

10. Living with SEGA and tuberous sclerosis complex

  • Attend regular TSC clinic appointments, which coordinate brain, kidney, skin, eye and heart checks
  • Know the warning signs of raised pressure and seek urgent help if they appear
  • Look after mouth hygiene while taking everolimus; use a soft toothbrush and alcohol-free mouthwash
  • Report fevers and infections promptly
  • Keep vaccinations up to date, but check with the team before live vaccines while on everolimus
  • Connect with TSC charities, which provide information, family support and research updates

Support at school and home

Area Ideas
Education Individual learning plans and specialist support where needed
Seizures A seizure care plan shared with school and carers
Behaviour and wellbeing Assessment for TSC-associated neuropsychiatric disorders (TAND)
Family Genetic counselling for parents and siblings

11. Frequently asked questions

Question Answer
Is SEGA cancer? No. It is a benign tumour that does not spread
Does everyone with TSC get SEGA? No. Only a minority develop one
Can adults get SEGA? New SEGAs after age 25 are rare, but existing ones need monitoring
Is everolimus lifelong? Often long-term, because SEGAs may regrow if it is stopped
Can SEGA come back after surgery? Sometimes, mainly if part of the tumour was left behind
Does SEGA cause epilepsy? Seizures in TSC are mainly caused by tubers, but a growing SEGA can make them worse
Can everolimus be taken with seizure medicines? Yes, but some seizure medicines change everolimus levels, so blood tests are needed
Is radiotherapy used? Rarely, because SEGA is benign and radiation can cause long-term harm in TSC
Can my other children have TSC? Genetic testing and counselling can assess this

12. Questions to ask your care team

  • Is the SEGA growing, and how fast?
  • Is there any sign of hydrocephalus?
  • Is surgery or everolimus better in my case?
  • How often will I need MRI scans?
  • What side effects should I watch for on everolimus?
  • Will everolimus interact with my other medicines?
  • Who should I call in an emergency?

Resources

  1. Danassegarane, G. et al. (2022) ‘Subependymal giant-cell astrocytoma: a surgical review in the modern era of mTOR inhibitors’, Neurochirurgie, 68(6), pp. 627-636.
  2. Franz, D.N. et al. (2013) ‘Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial’, The Lancet, 381(9861), pp. 125-132.
  3. Franz, D.N. et al. (2014) ‘Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study’, The Lancet Oncology, 15(13), pp. 1513-1520.
  4. National Cancer Institute (2026) Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.